AXIM — Axim Biotechnologies Share Price
0.000.00%
Last trade - 00:00- $2.89m
- $9.26m
- $0.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 25.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -3987.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.06 | 0.01 | 0.04 | n/a | n/a | -27.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Axim Biotechnologies, Inc. is a vertically integrated research and development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. Its core competencies include development of rapid lateral flow immunoassays, reagents, and monoclonal antibody development for such assays. Its product categories include Eye Health, wherein the Company acquired two FDA cleared tests for dye eye disease and has internally developed a third assay; and SARS-CoV-2 neutralizing antibody tests. The Company is focused on developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including SARS-Cov-2, Lactoferrin, IgE, Lacritin, and MMP-9. Its platform capability can also be applied to rapid testing for vaccine candidates. Its platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 18th, 2010
- Public Since
- April 9th, 2013
- No. of Shareholders
- 156
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 291,458,824
- Address
- 6191 Cornerstone Court, E, Suite 114, SAN DIEGO, 92121
- Web
- https://aximbiotech.com/
- Phone
- +1 2127510001
- Auditors
- RBSM LLP
Upcoming Events for AXIM
Q3 2024 Axim Biotechnologies Inc Earnings Release
Similar to AXIM
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the Axim Biotechnologies share price?
As of Today at 19:29 UTC, shares in Axim Biotechnologies are trading at $0.01. This share price information is delayed by 15 minutes.
How has the Axim Biotechnologies share price performed this year?
Shares in Axim Biotechnologies last closed at $0.01 and the price had moved by -77.27% over the past 365 days. In terms of relative price strength the Axim Biotechnologies share price has underperformed the S&P500 Index by -80.93% over the past year.
What are the analyst and broker recommendations for Axim Biotechnologies?
There is no consensus recommendation for this security.
What is the Axim Biotechnologies dividend yield?
Axim Biotechnologies does not currently pay a dividend.
Does Axim Biotechnologies pay a dividend?
Axim Biotechnologies does not currently pay a dividend.
When does Axim Biotechnologies next pay dividends?
Axim Biotechnologies does not currently pay a dividend.
How do I buy Axim Biotechnologies shares?
To buy shares in Axim Biotechnologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Axim Biotechnologies?
As of the previous close price of $0.01, shares in Axim Biotechnologies had a market capitalisation of $2.19m.
Where are Axim Biotechnologies shares listed?
Here are the trading details for Axim Biotechnologies:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AXIM
What kind of share is Axim Biotechnologies?
Based on an overall assessment of its quality, value and momentum Axim Biotechnologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Axim Biotechnologies share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Axim Biotechnologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Axim Biotechnologies. Over the past six months, its share price has underperformed the S&P500 Index by -67.03%.
As of the last closing price of $0.01, shares in Axim Biotechnologies were trading -54.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Axim Biotechnologies PE Ratio?
The Axim Biotechnologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Axim Biotechnologies?
We do not have data on Axim Biotechnologies' directors